# US 6,730,702 B1 · Therapeutic agents for inflammatory diseases of intestine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,702 B1
- Document ID: US6730702B1
- Status: Granted
- Kind: B1
- Application number: 10/129,361
- Filed: 2002-05-03
- Granted: 2004-05-04
- Earliest claimed: 1999-11-11
- Assignees: Tanabe Seiyaku Co., Ltd.
- Inventors: Toru Kono; Masafumi Nomura
- Web page: https://patentgrep.com/patent/US6730702B1

## CPC

- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a novel agent for prophylaxis or treatment of inflammatory bowel diseases for oral administration or intra-intestinal infusion, which comprises as an active ingredient a compound of the formula (I): or a pharmaceutically acceptable salt thereof; a use of said active ingredient in preparation of an agent for prophylaxis or treatment of inflammatory bowel diseases; and a method for prophylaxis or treatment of inflammatory bowel diseases.

## Claims

### Claim 1

A method for treatment of inflammatory bowel diseases, which comprises administering an effective amount of a compound of the formula (I)
or a pharmaceutically acceptable salt thereof to a patient suffering from an inflammatory bowel disease.

### Claim 2 (depends on 1)

The method for treatment according to claim 1, wherein the pharmaceutically acceptable salt of the compound of the formula (I) is sulfodehydroabietic acid monosodium salt.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the inflammatory bowel disease is a disease selected from the group consisting of an intestinal lesion accompanied by Crohn's disease or Behçet's disease, ulcerative colitis, hemorrhagic rectal ulcer and ileum pouchitis.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the inflammatory bowel disease is an intestinal lesion accompanied by Crohn's disease.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the intestinal lesion accompanied by Crohn's disease is fistula.

### Claim 6 (depends on 3)

The method according to claim 3, wherein the inflammatory bowel disease is an intestinal lesion accompanied by Behçet's disease.
